Abstract
One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum. Copyright © 1983 American Cancer Society
Cite
CITATION STYLE
Lipton, A., Harvey, H. A., Lawrence, B., Gottlieb, R., Kukrika, M., Dixon, R., … White, D. S. (1983). Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Cancer, 51(1), 57–60. https://doi.org/10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
